Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
The Doctors of USC
A Phase I/II Study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.
Open to Accrual
Defintions of terms and FAQ about clinical trials.
David Quinn, M.D.
Other Trial Staff:
Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Ernesto Duverger, D.M.
to see study documents.
You may participate in this study if:
Must have histologically or cytologically confirmed locally advanced or unresectable metastatic urothelial cancer
18 y/o and above
Life expectancy at least 6 mos
ECOG Performance Status 0-2
Absolute Neutrophil must be more than 1000; Platelets must be more than 100,000; Hemoglobin must be more than or equal to 9.0
Total bilirubin must be less than or equal to 1.5 ULN; AST/ALT must be less than or equal to 2.5 x ULN
Men & women of child-bearing potential must use adequate contraception (hormonal, barrier method or abstinence)
For Ph I of the study (Dose Levels 1 or 2): may have 2 or less prior treatments
For Ph II of the study and Dose Level 3 of Ph I: Must have measurable disease. Must not have any prior therapy for advanced disease, except chemotherapy in the adjuvant setting & last dose must have been more than 6 mos
Patients who are taking drugs that may affect the activity or PK of E7389 Halichondrin analog may be eligible after review
Must sign Informed Consent (including HIPAA authorization)
You may not participate in this study if:
Taking other investigational agents
Has untreated or unstable brain metastases
Has uncontrolled intercurrent illness including: ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia or psychiatric illness or social situations that would limit protocol compliance
Pregnant or breastfeeding
HIV positive and is on combination antiretroviral therapy or with CD4+ of less than or equal to 500/mm3
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.